MALT

MI 2 binds directly to MALT1 and suppresses activated B cell-like diffuse large B cell lymphoma (ABC-DLBCL) in vitro and in vivo.

MLT-747 is a potent, selective, allosteric inhibitor of MALT1, binds MALT1 in the allosteric Trp580 pocket, with an IC50 of 14 nM.

MLT-748 is a potent, selective and allosteric inhibitor of MALT1, binds MALT1 in the allosteric Trp580 pocket, with an IC50 of 5 nM.

SGR-1505 is a small molecule inhibitor targeting MALT1, effectively modulating the NF-κB signaling pathway. This compound demonstrates significant anti-proliferative and antitumor activities by inhibiting MALT1 enzymatic activity, leading to alterations in cell cycle progression, DNA damage response, and apoptosis-related gene expression in in vivo tumor models. SGR-1505 exhibits both tumorostatic and regressive effects in activated B cell-like diffuse large B cell lymphoma (ABC-DLBCL) xenograft models. It is a valuable tool for research into activated B-cell-like diffuse large B-cell lymphoma, non-Hodgkin B-cell lymphomas, chronic lymphocytic leukemia, and mature B cell neoplasms.

Safimaltib is a potent and selective allosteric inhibitor of MALT1 protease. It exhibits significant biological activity by hindering MALT1's function, which may contribute to tumor stasis in various cancer models. This compound is valuable for research applications exploring the role of MALT1 in oncogenesis and potential therapeutic interventions in malignancies driven by aberrant MALT1 activity.

MLT-985 is a selective allosteric inhibitor of MALT1, demonstrating an IC50 value of 3 nM. This compound effectively suppresses cell proliferation and intervenes in aberrant signaling associated with the CARD11/BCL10/MALT1 complex. MLT-985 is applicable in research focused on cancer, particularly in the study of B cell malignancies.

PROTAC MALT1 Degrader-1 is a selective degrader targeting MALT1 through the use of the PROTAC (proteolysis targeting chimera) technology. This compound facilitates the ubiquitination and subsequent proteasomal degradation of MALT1, making it a valuable tool for studies focused on lymphoma and related malignancies. Its mechanism of action enables the investigation of MALT1's role in cellular processes and therapeutic strategies for lymphoma treatment.

MLT-943 is a selective and orally active inhibitor of MALT1 protease. It effectively inhibits stimulated IL-2 secretion in peripheral blood mononuclear cells (PBMC) and whole blood, demonstrating consistent IC50 values across species (0.07-0.09 μM in PBMC and 0.6-0.8 μM in whole blood). With its notable anti-inflammatory properties, MLT-943 is a valuable reagent for investigating FcγR-mediated inflammatory processes.

Z-VRPR-FMK is an irreversible inhibitor of the MALT1 protein. It effectively inhibits the growth and invasion of diffuse large B-cell lymphoma by blocking MALT1-induced NF-κB activation and matrix metalloproteinase (MMP) expression. This makes Z-VRPR-FMK a valuable tool for research investigating the role of MALT1 in oncogenesis and therapeutic strategies targeting NF-κB pathways.

MLT-231 is a potent allosteric inhibitor of MALT1, demonstrating high selectivity with an IC50 of 9 nM. This compound effectively prevents the cleavage of endogenous BCL10, with an IC50 of 160 nM. MLT-231 shows promising antitumor activity in mouse models of activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL), making it a valuable tool for research into therapeutic strategies targeting MALT1-related pathways.

MALT1-IN-11 is a potent MALT1 protease inhibitor with an IC50 of less than 10 nM. This compound effectively inhibits interleukin-10 (IL-10) secretion, with an IC50 range of 10-100 nM. MALT1-IN-11 is utilized in research focused on cancer, autoimmune diseases, and inflammatory disorders, providing valuable insights into the role of MALT1 in these pathological conditions.

MALT1-IN-9 is a selective MALT1 protease inhibitor, demonstrating an IC50 of less than 500 nM in Raji MALT1-GloSensor cells. This compound exhibits significant anticancer activity, making it a valuable tool for research focused on targeting MALT1 in various oncological studies. Its efficacy supports investigations into the role of MALT1 in cancer progression and therapeutic development.

MALT1-IN-5 is a potent inhibitor of the MALT1 protease, targeting the NF-κB signaling pathway. This compound has demonstrated significant biological activity in disrupting MALT1-dependent signaling processes. MALT1-IN-5 is primarily utilized in cancer research to investigate the role of MALT1 in tumorigenesis and its potential as a therapeutic target.

(R)-MALT1-IN-7 is a selective MALT1 protease inhibitor, designed for investigating the role of MALT1 in various biological processes. It exhibits potent inhibitory activity, making it valuable for cancer research, particularly in studies exploring the underlying mechanisms of tumorigenesis and potential therapeutic interventions. This compound serves as a useful tool in elucidating the function of MALT1 in both normal and pathological cellular contexts.

MALT1-IN-3 is a selective MALT1 protease inhibitor with a potent IC50 of 0.06 μM. This compound demonstrates inhibitive effects on human IL-6 and IL-10 production in OCI-LY3 cells, exhibiting IC50 values of 0.14 μM and 0.13 μM, respectively. MALT1-IN-3 is valuable for research into gene expression regulation, immune response modulation, and potential therapeutic strategies in various malignancies.

(R)-MLT-985 is a selective allosteric inhibitor of MALT1, exhibiting an IC50 value of 3 nM. This compound effectively suppresses cell proliferation and disrupts aberrant signaling initiated by the CARD11/BCL10/MALT1 complex. (R)-MLT-985 is primarily utilized in research related to cancer, particularly in the study of B cell malignancies.

NVS-MALT1 is an allosteric inhibitor of the MALT1 protein, disrupting its activity and providing a valuable tool for studying MALT1-mediated signaling pathways. This compound demonstrates the ability to modulate NF-κB activation and enhance apoptosis in cancer cells, making it relevant for research in oncology and immune response. It is particularly useful in investigations focusing on B-cell lymphoma and other MALT1-associated diseases.

Ocipumaltib is a potent inhibitor of mucosa-associated lymphoid tissue protein 1 (MALT1), which plays a crucial role in various signaling pathways. This compound exhibits significant antitumor activity, making it a valuable tool for cancer research. Additionally, Ocipumaltib is applicable in the study of infection, neurological disorders, and hematological diseases, providing insights into MALT1's involvement in these conditions.

(S)-MALT1-IN-5 is a potent inhibitor targeting the MALT1 protease. This compound effectively inhibits MALT1 activity, which may provide therapeutic insights for conditions associated with aberrant T cell receptor and B cell receptor signaling, as well as cancers and inflammatory diseases linked to MALT1 dysregulation. (S)-MALT1-IN-5 is a valuable tool for researching MALT1-related disease mechanisms and developing potential interventions.

Z-Val-Arg-Pro-DL-Arg-Fluoromethylketone is a potent inhibitor of MALT1, a key protein involved in various signaling pathways. This compound effectively inhibits cell proliferation and migration, demonstrating significant anticancer activity. It is valuable for research applications focused on cancer biology and therapeutic strategies targeting MALT1-related pathways.

MALT1-IN-8 is a potent inhibitor of MALT1 protease, demonstrating an IC50 of 2 nM. This compound effectively inhibits the proliferation of OCI-LY3 lymphoma cells, with an IC50 value of 1.16 μM. MALT1-IN-8 shows potential for anticancer applications, making it a valuable tool for research in lymphoma and other malignancies involving MALT1.

(R)-MALT1-IN-3 is a selective MALT1 protease inhibitor, exhibiting a potent IC50 of 20 nM. Additionally, this compound demonstrates significant inhibition of interleukin-6 and interleukin-10 with IC50 values of 60 nM and 40 nM, respectively, in OCI-LY3 cells. It serves as a valuable tool for exploring the role of MALT1 in various biological processes, particularly in the context of inflammatory pathways and cancer research.

MALT1-IN-6 is a selective inhibitor of MALT1 protease, exhibiting a Ki value of 9 nM. This compound demonstrates significant anticancer activity, making it a valuable tool for research focused on cancer therapeutics and the study of signaling pathways modulated by MALT1. Its potency and specificity may facilitate investigations into the roles of MALT1 in various malignancies.

RGT-068A is a selective and orally bioavailable inhibitor of MALT1 (Mucosa-associated lymphoid tissue lymphoma translocation protein 1). This compound demonstrates potent inhibitory activity against MALT1, which is essential for NF-κB signaling in various hematological malignancies and inflammatory diseases. RGT-068A serves as a valuable tool for research into therapeutic strategies targeting MALT1 in cancer and autoimmune disorders.

MALT1-IN-7 is a potent inhibitor of the MALT1 protease, which plays a crucial role in various oncogenic signaling pathways. Its ability to selectively inhibit MALT1 makes it a valuable tool for investigating the mechanisms underlying cancer development and progression. This compound is particularly relevant for research applications focused on tumor biology and therapeutic strategies targeting MALT1-dependent pathways.

MALT1-IN-14 is a potent MALT1 inhibitor, exhibiting an IC50 value of 0.081 μM. This compound demonstrates significant inhibition of MALT1's protease activity, making it valuable for studies investigating the role of MALT1 in inflammatory responses and lymphocyte activation. Its application extends to research in various diseases, including hematological malignancies and autoimmune disorders.